Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
  • Commercial

Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences

BioSpace

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since

CommercialMetabolic & GLP-1Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

BioSpace

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
Next: Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

Related Stories

  • Commercial

CVS obesity drug deal puts Lilly on equal footing with Novo

pharminent May 28, 2026
  • Commercial

Kardigan targets IPO to support cardiology pipeline progression

pharminent May 27, 2026
  • Commercial

Lilly UK recruits ex-England cricketer as obesity champion

pharminent May 15, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.